Gestodene

Summary

Gestodene (CHEMBL1213583) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 13
• Chemistry: 310.4 Da · C21H26O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1213583
Name	Gestodene
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3033968
Molecular formula	C21H26O2
Molecular weight	310.4
InChIKey	SIGSPDASOTUPFS-XUDSTZEESA-N

SMILES: CC[C@]12CC[C@H]3[C@H]([C@@H]1C=C[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34

IUPAC name: (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one

Also known as: Gestodene, Gestodeno, SH B 331, SH-B-331, GESTODENE, SID144205785, SID170466131, gestodene, GestodeneÊ, GestodeneÂ

Patent coverage: 1,576 distinct patent families (5,754 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Androgen receptor, Estrogen receptor, Progesterone receptor, Sodium-dependent serotonin transporter, Mu-type opioid receptor, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
AR	8.52	AC50	3	nM	CHEMBL_ACT_25203428
PGR	8.52	AC50	3	nM	CHEMBL_ACT_25204361
ESR1	5.92	AC50	1200	nM	CHEMBL_ACT_25138928
P62813	5.67	AC50	2160	nM	CHEMBL_ACT_25207931
SLC6A4	5.34	AC50	4590	nM	CHEMBL_ACT_25151397

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	3
Not specified	2
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00910637	PHASE3	COMPLETED	Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles
NCT00914693	PHASE3	COMPLETED	EU/LA Pearl Index Study - Transdermal Contraceptive Patch
NCT00920985	PHASE3	COMPLETED	US Cycle Control and Blood Pressure Study
NCT00729404	PHASE2	TERMINATED	Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene
NCT00873483	PHASE2	COMPLETED	US Ovulation Inhibition Study in Obese Women
NCT00915915	PHASE2	COMPLETED	Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)
NCT00933179	PHASE2	COMPLETED	FC Patch Low: Metabolism Study
NCT01204190	PHASE2	COMPLETED	Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.
NCT02550977	PHASE2	COMPLETED	Russia/Ukraine Suppression of Ovarian Activity Study
NCT03881904	PHASE1/PHASE2	UNKNOWN	OCP Pretreatment in PCOS Patients Undergoing ICSI Using Antagonist Protocol
NCT01083264	PHASE1	COMPLETED	Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites
NCT06396208	Not specified	COMPLETED	Quick-starting of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition
NCT06396221	Not specified	COMPLETED	Quick-starting of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).